GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45
GENTAUR U.S.A Genprice Inc 6017 Snell Ave, Ste 357, SanJose, CA 95123
Tel (408) 780-0908, Fax (408) 780-0908, email@example.com
Index / US Biomax / Esophageal cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores / Product Detail : ES1002 Esophageal cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores
#ES1002 Esophageal cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores
Product name : Esophageal cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores
Catalog number : ES1002
Supplier name : US Biomax
Data sheet: Ask more or other datasheet now !
About this Product :Esophageal cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores antibody storage GENTAUR recommends for long therm storage to freeze at -24 C. For short time storage up to 30 days we suggest fridge storage at 1 to 10 C. Prevent multiple freeze taw cycles of Esophageal cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores.
More Details about
|Microarray Panel:||Esophageal carcinoma tissue microarray for antibody screening, containing 40 cases of esophageal carcinoma (39 squamous cell carcinoma, 1 adenocarcinoma), 10 normal tissue, duplicate cores per case, divided into two identical 50 cores arrays|
|Layout:||10 cols × 10 rows|
|Core Diameter:||1 mm|
|Quality Control:||Anti-Actin confirmed|
|Applications:||Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page.|
|Notes:||Unless specified, all TMA slides are not coated with extra layer of paraffin (tissue cores can be easily seen on the glass), so there is no need to bake, can be directly put into xylene for de-paraffin procedure.|
*Tissue Microarray Slide Types:
- Unstained: unstained paraffin tissue microarray slide.
- Trial: tissue microarray trial slide. 10% - 25% of cores missing. Good for titrating antibody dilution and experiment conditions. Limited numbers are available, to 2 per item per order. Test slides (tissue arrays with catalog numbers ending with 241 or 242) are recommended as a substitute.
- H & E: Hematoxylin and Eosin stained tissue microarray slide.
Contact us about this product :
Our team will respond you as soon as possible !
We have also other products like : Esophageal cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 50 cases_100 cores
52062 Aachen Deutschland
Support Karolina Elandt
Fax: (+49) 241 56 00 47 88
Logistic :0241 40 08 90 86
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
firstname.lastname@example.org | Gentaur
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123
Canada Montreal +15149077481
Ceská republika Praha +420246019719
Finland Helsset +358942419041
Magyarország Budapest +3619980547
US New York+17185132983
WP1589: Folate-Alcohol and Cancer Pathway
WP1968: genetic alternations of lung cancer
WP1971: Integrated Cancer pathway
WP1984: Integrated Breast Cancer Pathway
WP2107: pathways in human cancer
WP2256: Integrated Pancreatic Cancer Pathway
WP2263: Prostate Cancer
WP2291: Deregulation of Rab and Rab Effector Genes in Bladder Cancer
WP2335: sGC Cancer
WP2361: Gastric cancer network 1
WP2363: Gastric cancer network 2
WP2367: Private Pancreatic Cancer
WP2377: Integrated Pancreatic Cancer Pathway
WP2411: Cancer prevention Q
WP2429: Cancer prevention Q
Related Genes :
[TP53 P53] Cellular tumor antigen p53 (Antigen NY-CO-13) (Phosphoprotein p53) (Tumor suppressor p53)
[BRCA2 FACD FANCD1] Breast cancer type 2 susceptibility protein (Fanconi anemia group D1 protein)
[LZTS1 FEZ1] Leucine zipper putative tumor suppressor 1 (F37/esophageal cancer-related gene-coding leucine-zipper motif) (Fez1)
[TGFBR2] TGF-beta receptor type-2 (TGFR-2) (EC 18.104.22.168) (TGF-beta type II receptor) (Transforming growth factor-beta receptor type II) (TGF-beta receptor type II) (TbetaR-II)
[DLEC1 DLC1] Deleted in lung and esophageal cancer protein 1 (Deleted in lung cancer protein 1) (DLC-1)
[ALOX12 12LO LOG12] Arachidonate 12-lipoxygenase, 12S-type (12S-LOX) (12S-lipoxygenase) (EC 22.214.171.124) (Lipoxin synthase 12-LO) (EC 3.3.2.-) (Platelet-type lipoxygenase 12)
[TMPRSS11A ECRG1 HATL1 HESP] Transmembrane protease serine 11A (EC 3.4.21.-) (Airway trypsin-like protease 1) (Epidermal type-II transmembrane serine protease) (Esophageal cancer-susceptibility gene 1 protein)
[RHOA ARH12 ARHA RHO12] Transforming protein RhoA (Rho cDNA clone 12) (h12)
[WWOX FOR SDR41C1 WOX1] WW domain-containing oxidoreductase (EC 1.1.1.-) (Fragile site FRA16D oxidoreductase) (Short chain dehydrogenase/reductase family 41C member 1)
[CLE1 2B10 HSP1 SYV46] CLAVATA3/ESR (CLE)-related protein 1 (CLE-like peptide 1) (Hg-SYV46) (Esophageal gland cell secretory protein 1)
[RNF6 SPG2] E3 ubiquitin-protein ligase RNF6 (EC 6.3.2.-)
[SOX2] Transcription factor SOX-2
[DMBT1 GP340] Deleted in malignant brain tumors 1 protein (Glycoprotein 340) (Gp-340) (Hensin) (Salivary agglutinin) (SAG) (Surfactant pulmonary-associated D-binding protein)
[FGF8 AIGF] Fibroblast growth factor 8 (FGF-8) (Androgen-induced growth factor) (AIGF) (Heparin-binding growth factor 8) (HBGF-8)
[CASP8 MCH5] Caspase-8 (CASP-8) (EC 126.96.36.199) (Apoptotic cysteine protease) (Apoptotic protease Mch-5) (CAP4) (FADD-homologous ICE/ced-3-like protease) (FADD-like ICE) (FLICE) (ICE-like apoptotic protease 5) (MORT1-associated ced-3 homolog) (MACH) [Cleaved into: Caspase-8 subunit p18; Caspase-8 subunit p10]
[Lzts1 Fez1] Leucine zipper putative tumor suppressor 1 (F37/Esophageal cancer-related gene-coding leucine-zipper motif) (Fez1)
[C16orf62 101F10.2] UPF0505 protein C16orf62 (Esophageal cancer-associated protein)
[Ecrg4] Augurin (Esophageal cancer-related gene 4 protein homolog)
[CDKN2A CDKN2 MTS1] Cyclin-dependent kinase inhibitor 2A (Cyclin-dependent kinase 4 inhibitor A) (CDK4I) (Multiple tumor suppressor 1) (MTS-1) (p16-INK4a) (p16-INK4) (p16INK4A)
[GRB7] Growth factor receptor-bound protein 7 (B47) (Epidermal growth factor receptor GRB-7) (GRB7 adapter protein)
[FZD4] Frizzled-4 (Fz-4) (hFz4) (FzE4) (CD antigen CD344)
[YAP1 YAP65] Transcriptional coactivator YAP1 (Yes-associated protein 1) (Protein yorkie homolog) (Yes-associated protein YAP65 homolog)
[LTA4H LTA4] Leukotriene A-4 hydrolase (LTA-4 hydrolase) (EC 188.8.131.52) (Leukotriene A(4) hydrolase)
[16D10 MSP16] CLAVATA3/ESR (CLE)-related protein 16D10 (Esophageal gland cell secretory protein 16)
[Ecrg4] Augurin (Esophageal cancer-related gene 4 protein homolog)
[C2orf40 ECRG4 UNQ761/PRO1508] Augurin (Esophageal cancer-related gene 4 protein)
[AURKA AIK AIRK1 ARK1 AURA AYK1 BTAK IAK1 STK15 STK6] Aurora kinase A (EC 184.108.40.206) (Aurora 2) (Aurora/IPL1-related kinase 1) (ARK-1) (Aurora-related kinase 1) (hARK1) (Breast tumor-amplified kinase) (Serine/threonine-protein kinase 15) (Serine/threonine-protein kinase 6) (Serine/threonine-protein kinase aurora-A)
[FZD5 C2orf31] Frizzled-5 (Fz-5) (hFz5) (FzE5)
[MSR1 SCARA1] Macrophage scavenger receptor types I and II (Macrophage acetylated LDL receptor I and II) (Scavenger receptor class A member 1) (CD antigen CD204)
[NLRP3 C1orf7 CIAS1 NALP3 PYPAF1] NACHT, LRR and PYD domains-containing protein 3 (Angiotensin/vasopressin receptor AII/AVP-like) (Caterpiller protein 1.1) (CLR1.1) (Cold-induced autoinflammatory syndrome 1 protein) (Cryopyrin) (PYRIN-containing APAF1-like protein 1)
 Patient-Reported Outcomes (PROs) in NRG Oncology/RTOG 0436: A Phase 3 Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Esophageal Cancer Treated Without Surgery.
 A Randomized Phase 2 Trial Estimating the Optimal Radiation Volume of Postoperative Radiation Therapy for Patients With Locoregionally Advanced Thoracic Esophageal Squamous Cell Carcinoma-A Preliminary Report (NCT01391572).
 Preliminary Results of a Phase 2 Study of Definitive Chemoradiation Therapy Using S-1 for Esophageal Squamous Cell Carcinoma Patients.
 PD-L1 is Prognostic Factor of Human Esophageal Squamous Cell Carcinoma and Its Association With EGFR in Radiation Therapy.
 CAFs-Secreted CXCL1 Mediated Radioresistance by Regulating DNA Damage Response in an ROS-Dependent Manner in Esophageal Squamous Cell Carcinoma.
 Impact of Radiation Dose Escalation for Cervical Esophageal Cancer: A National Cancer Data Base (NCDB) Analysis.
 Neoadjuvant Chemoradiation Dose and Outcomes in Esophageal Cancers, a National Cancer Data Base Study.
 Comparative Outcomes of Upfront Surgery, Neoadjuvant Chemoradiation, or Definitive Chemoradiation for T2N0M0 Esophageal Adenocarcinomas From The National Cancer Data Base.
 Nomogram and Recursive Partitioning Analysis to Predict Overall Survival in Patients With Stage IIB-III Thoracic Esophageal Carcinoma After Esophagectomy.
 Overall Survival Benefit of Intensity Modulated Compared With 3D-Conformal Radiation Therapy in the Definitive Management of Esophageal Cancer: Analysis of the National Cancer Data Base (NCDB).
Enter catalog number :